Clinical trials: Shy-Drager Syndrome
Amyotrophic Lateral Sclerosis, Brainstem Stroke
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit
This project adds to non-invasive BCIs for communication for adults with severe speech and physical impairments due to neurodegenerative diseases.
- Conditions
- Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism
- Trial name
- BCI-FIT (NCT04468919)
- Testing
- BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Multisystemic Atrophy
Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy.
- Trial name
- MSAJOY (NCT01044992)
- Testing
- H215O PET, Levodopa
- Where
- 4 sites in France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Parkinson's Disease, Parkinsonian Disorders
Gait Analysis in Neurological Disease
The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with…
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- NCT02994719
- Testing
- Anti-Parkinson medication, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Parkinson Disease, Multiple System Atrophy
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime…
- Conditions
- Parkinson Disease, Multiple System Atrophy, REM Sleep Behavior Disorder, Pure Autonomic Failure
- Trial name
- NCT02640339
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson Disease, Multiple System Atrophy
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
An experimental drug called L-DOPS increases production in the body of a messenger chemical called norepinephrine. Cells in the brain that make norepinephrine are often gone in Parkinson disease.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
- Trial name
- NCT00547911
- Testing
- Droxidopa, Carbidopa, Entacapone
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alpha-Synucleinopathy, Parkinson's Disease
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
The overall goal of this protocol is to evaluate [18F]MNI-1216 (also known as [18F]ACI-12589) as an α-synuclein targeted radiopharmaceutical in 3 parts as follows: Part 1: first in human (FiH) imaging Optional Part 2: expansion…
- Conditions
- Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
- Trial name
- NCT06445465
- Testing
- [18F]MNI-1216
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Multiple System Atrophy
High-Altitude Neurodegeneration Cohort (HANC) Study
Chronic physiological hypoxia has been implicated in the pathogenesis of multiple system atrophy (MSA), a fatal neurodegenerative disorder of unknown etiology.
- Trial name
- HANC (NCT07657520)
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- West China Hospital
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Parkinson's Disease, Parkinsonism
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism.
- Conditions
- Parkinson's Disease, Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- VISMEMO-PD (NCT07827963)
- Testing
- Multimodal visuospatial and topographical memory assessment
- Where
- 3 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Parkinson Disease, Multiple System Atrophy
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis - Part 2
Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology.
- Trial name
- Voice4PD-MSA (NCT05807373)
- Testing
- voice recordings
- Where
- 2 sites in France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy
Quality of Life of Caregivers and Patients Suffering From Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder that cause as other neurodegenerative diseases profound declines in functioning and thus, require caregiving for assistance with daily living.
- Trial name
- QUA2-AMS (NCT04965922)
- Testing
- Multimodal intervention
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy
Natural History and Disease Progression Biomarkers of Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease characterised by a variable combination of parkinsonism, cerebellar impairment and autonomic dysfunction.
- Trial name
- ASPIRE-MSA (NCT04229173)
- Testing
- MRI acquisition, DAT-SPECT, blood sample, cerebrospinal fluid (optional)
- Where
- 10 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Parkinson Disease, Progressive Supranuclear Palsy(PSP)
Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
This is an observational longitudinal study in 4 cohorts of patients with Parkinsonian syndromes, who are visiting the Movement Disorders outpatient clinics.
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy
- Trial name
- PARATROOPER (NCT06597071)
- Testing
- NeuraLight PD, NeuraLight PSP, NeuraLight MSA
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuraLight
Parkinson's Disease, Progressive Supranuclear Palsy(PSP)
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.
- Conditions
- Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
- Trial name
- NCT07392411
- Testing
- video recording
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Parkinson Disease, Dementia With Lewy Bodies
Optimization of Morphomer-based Alpha-synuclein PET Tracers
The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer. The research phase will exploit ACI's proprietary MorphomerTM library and extensively optimized screening workflow.
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05067192
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for…
- Trial name
- NCT06890377
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Min Zhao,MD
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian…
- Conditions
- PARKINSON DISEASE (Disorder), Atypical Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
- Trial name
- BIOMARK-PS (NCT07604883)
- Where
- 2 sites in Poland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Institute of Molecular and Cell Biology in Warsaw